Characterization of UDP-glucuronosyltransferase 2A1 (UGT2A1) variants and their potential role in tobacco carcinogenesis

Pharmacogenetics and Genomics

Volumn 21, Issue 2, 2011, Pages 55-65

  Bushey, Ryan T ^a,c   Chen, Gang ^a,c   Blevins Primeau, Andrea S ^a,c   Krzeminski, Jacek ^b   Amin, Shantu ^b   Lazarus, Philip ^a,c  

^a Molecular Epidemiology and Cancer Control Program   (United States)

^b PENN STATE CANCER INSTITUTE   (United States)

^c PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

aerodigestive tract; lung carcinogenesis; metabolism; polycyclic aromatic hydrocarbons; single nucleotide polymorphism; tobacco; UDP glucuronosyltransferase 2A1

Indexed keywords

1 HYDROXY BENZO[A]PYRENE; 4 (METHYLNITROSAMINO) 1 (3 PYRIDYL) 1 BUTANOL; 5 METHYLCHRYSENE 1,2 DIOL; 7,8 DIHYDROXYBENZO[A]PYRENE; BENZO[A]PYRENE DERIVATIVE; CARCINOGEN; GLUCURONIDE; GLUCURONOSYLTRANSFERASE; POLYCYCLIC AROMATIC HYDROCARBON; TOBACCO SMOKE; UNCLASSIFIED DRUG; URIDINE DIPHOSPHATE;

ARTICLE; BRAIN; BREAST; CARCINOGENESIS; CELL FREE SYSTEM; CELL STRAIN HEK293; COLON; CONTROLLED STUDY; DETOXIFICATION; DIGESTIVE SYSTEM; EMBRYO; ENZYME ACTIVITY; ESOPHAGUS; GENE EXPRESSION; GENE FUNCTION; GENE OVEREXPRESSION; GENETIC TRAIT; GENETIC VARIABILITY; GLUCURONIDATION; HUMAN; HUMAN CELL; KIDNEY; LARYNX; LIVER; LUNG; MISSENSE MUTATION; NUCLEOTIDE SEQUENCE; OLFACTORY TRACT; PANCREAS; PRIORITY JOURNAL; PROSTATE; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; TARGET ORGAN; TOBACCO; TONSIL; TRACHEA; UDP GLUCURONOSYLTRANSFERASE 2A1 GENE; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; WILD TYPE;

NICOTIANA TABACUM;

EID: 78751612798     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e328341db05     Document Type: Article

References (38)

1. Ren Q, Murphy SE, Zheng Z, Lazarus P. O-Glucuronidation of the lung carcinogen 4-(methylnitrosamino)-1- (3-pyridyl)-1-butanol (NNAL) by human UDP-glucuronosyltransferases 2B7 and 1A9. Drug Metab Dispos 2000; 28:1352-1360.
2. Gueraud F, Paris A. Glucuronidation: a dual control. Gen Pharmacol 1998; 31:683-688. (Pubitemid 28520043)
3. Tephly TR, Burchell B. UDP-glucuronosyltransferases: a family of detoxifying enzymes. Trends Pharmacol Sci 1990; 11:276-279.
4. Jin C, Miners JO, Lillywhite KJ, Mackenzie PI. Complementary deoxyribonucleic acid cloning and expression of a human liver uridine diphosphate-glucuronosyltransferase glucuronidating carboxylic acid-containing drugs. J Pharmacol Exp Ther 1993; 264:475-479.
5. Mackenzie PI, Bock KW, Burchell B, Guillemette C, Ikushiro S, Iyanagi T, et al. Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily. Pharmacogenet Genomics 2005; 15:677-685.
6. Beaulieu M, Levesque E, Tchernof A, Beatty BG, Belanger A, Hum DW. Chromosomal localization, structure, and regulation of the UGT2B17 gene, encoding a C19 steroid metabolizing enzyme. DNA Cell Biol 1997; 16:1143-1154.
7. Sneitz N, Court MH, Zhang X, Laajanen K, Yee KK, Dalton P, et al. Human UDP-glucuronosyltransferase UGT2A2: cDNA construction, expression, and functional characterization in comparison with UGT2A1 and UGT2A3. Pharmacogenet Genomics 2009; 19:923-934.
8. Jedlitschky G, Cassidy AJ, Sales M, Pratt N, Burchell B. Cloning and characterization of a novel human olfactory UDP-glucuronosyltransferase. Biochem J 1999; 340 (Pt 3):837-843.
9. Nishimura M, Naito S. Tissue-specific mRNA expression profiles of human phase I metabolizing enzymes except for cytochrome P450 and phase II metabolizing enzymes. Drug Metab Pharmacokinet 2006; 21:357-374.
10. Itaaho K, Mackenzie PI, Ikushiro S, Miners JO, Finel M. The configuration of the 17-hydroxy group variably influences the glucuronidation of beta-estradiol and epiestradiol by human UDP-glucuronosyltransferases. Drug Metab Dispos 2008; 36:2307-2315.
11. Sten T, Bichlmaier I, Kuuranne T, Leinonen A, Yli-Kauhaluoma J, Finel M. UDP-glucuronosyltransferases (UGTs) 2B7 and UGT2B17 display converse specificity in testosterone and epitestosterone glucuronidation, whereas UGT2A1 conjugates both androgens similarly. Drug Metab Dispos 2009; 37:417-423.
12. Chen G, Dellinger RW, Gallagher CJ, Sun D, Lazarus P. Identification of a prevalent functional missense polymorphism in the UGT2B10 gene and its association with UGT2B10 inactivation against tobacco-specific nitrosamines. Pharmacogenet Genomics 2008; 18:181-191.
13. Dellinger RW, Fang JL, Chen G, Weinberg R, Lazarus P. Importance of UDP-glucuronosyltransferase 1A10 (UGT1A10) in the detoxification of polycyclic aromatic hydrocarbons: decreased glucuronidative activity of the UGT1A10139Lys isoform. Drug Metab Dispos 2006; 34:943-949.
14. Gallagher CJ, Muscat JE, Hicks AN, Zheng Y, Dyer AM, Chase GA, et al. The UDP-glucuronosyltransferase 2B17 gene deletion polymorphism: sex-specific association with urinary 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol glucuronidation phenotype and risk for lung cancer. Cancer Epidemiol Biomarkers Prev 2007; 16:823-828.
15. The International HapMap Project. Nature 2003; 426:789-796.
16. Zheng Z, Park JY, Guillemette C, Schantz SP, Lazarus P. Tobacco carcinogen-detoxifying enzyme UGT1A7 and its association with orolaryngeal cancer risk. J Natl Cancer Inst 2001; 93:1411-1418.
17. Elahi A, Bendaly J, Zheng Z, Muscat JE, Richie JP Jr, Schantz SP, et al. Detection of UGT1A10 polymorphisms and their association with orolaryngeal carcinoma risk. Cancer 2003; 98:872-880.
18. Fang JL, Beland FA, Doerge DR, Wiener D, Guillemette C, Marques MM, et al. Characterization of benzo(a)pyrene-trans-7,8-dihydrodiol glucuronidation by human tissue microsomes and overexpressed UDP-glucuronosyltransferase enzymes. Cancer Res 2002; 62:1978-1986.
19. Wiener D, Fang JL, Dossett N, Lazarus P. Correlation between UDP-glucuronosyltransferase genotypes and 4-(methylnitrosamino)-1-(3-pyridyl)-1- butanone glucuronidation phenotype in human liver microsomes. Cancer Res 2004; 64:1190-1196.
20. Balliet RM, Chen G, Gallagher CJ, Dellinger RW, Sun D, Lazarus P. Characterization of UGTs active against SAHA and association between SAHA glucuronidation activity phenotype with UGT genotype. Cancer Res 2009; 69:2981-2989.
21. Sun D, Sharma AK, Dellinger RW, Blevins-Primeau AS, Balliet RM, Chen G, et al. Glucuronidation of active tamoxifen metabolites by the human UDP glucuronosyltransferases. Drug Metab Dispos 2007; 35:2006-2014. (Pubitemid 350010805)
22. Dellinger RW, Chen G, Blevins-Primeau AS, Krzeminski J, Amin S, Lazarus P. Glucuronidation of PhIP and N-OH-PhIP by UDP-glucuronosyltransferase 1A10. Carcinogenesis 2007; 28:2412-2418.
23. Blevins-Primeau AS, Sun D, Chen G, Sharma AK, Gallagher CJ, Amin S, et al. Functional significance of UDP-glucuronosyltransferase variants in the metabolism of active tamoxifen metabolites. Cancer Res 2009; 69:1892-1900.
24. Uchaipichat V, Mackenzie PI, Guo XH, Gardner-Stephen D, Galetin A, Houston JB, et al. Human udp-glucuronosyltransferases: isoform selectivity and kinetics of 4-methylumbelliferone and 1-naphthol glucuronidation, effects of organic solvents, and inhibition by diclofenac and probenecid. Drug Metab Dispos 2004; 32:413-423.
25. Jin CJ, Miners JO, Burchell B, Mackenzie PI. The glucuronidation of hydroxylated metabolites of benzo[a]pyrene and 2-acetylaminofluorene by cDNA-expressed human UDP-glucuronosyltransferases. Carcinogenesis 1993; 14:2637-2639. (Pubitemid 24016609)
26. Zheng Z, Fang JL, Lazarus P. Glucuronidation: an important mechanism for detoxification of benzo(a)pyrene metabolites in aerodigestive tract tissues. Drug Metab Dispos 2002; 30:397-403.
27. Luukkanen L, Mikkola J, Forsman T, Taavitsainen P, Taskinen J, Elovaara E. Glucuronidation of 1-hydroxypyrene by human liver microsomes and human UDP-glucuronosyltransferases UGT1A6, UGT1A7, and UGT1A9: development of a high-sensitivity glucuronidation assay for human tissue. Drug Metab Dispos 2001; 29:1096-1101.
28. Nakamura A, Nakajima M, Yamanaka H, Fujiwara R, Yokoi T. Expression of UGT1A and UGT2B mRNA in human normal tissues and various cell lines. Drug Metab Dispos 2008; 36:1461-1464.
29. Girard H, Butler LM, Villeneuve L, Millikan RC, Sinha R, Sandler RS, et al. UGT1A1 and UGT1A9 functional variants, meat intake, and colon cancer, among Caucasians and African-Americans. Mutat Res 2008; 644:56-63.
30. Butler LM, Sinha R, Millikan RC, Martin CF, Newman B, Gammon MD, et al. Heterocyclic amines, meat intake, and association with colon cancer in a population-based study. Am J Epidemiol 2003; 157:434-445.
31. Guillemette C, Ritter JK, Auyeung DJ, Kessler FK, Housman DE. Structural heterogeneity at the UDP-glucuronosyltransferase 1 locus: functional consequences of three novel missense mutations in the human UGT1A7 gene. Pharmacogenetics 2000; 10:629-644.
32. Kim PM, Wells PG. Genoprotection by UDP-glucuronosyltransferases in peroxidase-dependent, reactive oxygen species-mediated micronucleus initiation by the carcinogens 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and benzo(a)pyrene. Cancer Res 1996; 56:1526-1532.
33. Ockenga J, Vogel A, Teich N, Keim V, Manns MP, Strassburg CP. UDP glucuronosyltransferase (UGT1A7) gene polymorphisms increase the risk of chronic pancreatitis and pancreatic cancer. Gastroenterology 2003; 124:1802-1808.
34. Strassburg CP, Vogel A, Kneip S, Tukey RH, Manns MP. Polymorphisms of the human UDP-glucuronosyltransferase (UGT) 1A7 gene in colorectal cancer. Gut 2002; 50:851-856.
35. Lazarus P, Zheng Y, Aaron Runkle E, Muscat JE, Wiener D. Genotype-phenotype correlation between the polymorphic UGT2B17 gene deletion and NNAL glucuronidation activities in human liver microsomes. Pharmacogenet Genomics 2005; 15:769-778.
36. Nagar S, Remmel RP. Uridine diphosphoglucuronosyltransferase pharmacogenetics and cancer. Oncogene 2006; 25:1659-1672.
37. Miley MJ, Zielinska AK, Keenan JE, Bratton SM, Radominska-Pandya A, Redinbo MR. Crystal structure of the cofactor-binding domain of the human phase II drug-metabolism enzyme UDP-glucuronosyltransferase 2B7. J Mol Biol 2007; 369:498-511.
38. Laakkonen L, Finel M. A molecular model of the human UDP- glucuronosyltransferase 1A1, its membrane orientation, and the interactions between different parts of the enzyme. Mol Pharmacol 2010; 77:931-939.